文献速递乳腺癌

腔内信号轴全程靶向:HR+/HER2-转移性乳腺癌新一代内分泌与靶向治疗综述

Drugging the luminal axis end to end: A review of next-generation endocrine and targeted therapies in HR + /HER2- metastatic breast cancer.
PubMed 文献 · Eur J Cancer · 2026-10-23

该综述将HR+/HER2-转移性乳腺癌视为以ER转录为核心的互联信号网络,从ER药理多样化、慢性多节点阻断的耐受性天花板及基因组定义患者选择三方面解读近期进展,并提出耐药分类可作为持久、可耐受、生物标志物引导的垂直阻断治疗决策路线图。

要点

  • ER药理已分化为口服SERD、PROTAC降解剂、CERAN、SERCA、SERM及KAT6抑制等机制不同类别。
  • 最一致信号集中于ESR1突变场景,体现生物标志物门控开发。
  • 突变选择性PI3Kα抑制剂及CDK4/CDK2选择性药物通过提升选择性来突破耐受性天花板。

核心结论

  • 当代耐药分类可作为HR+/HER2-转移性乳腺癌腔内信号轴持久、可耐受、生物标志物引导垂直阻断的治疗决策路线图。

研究设计与样本

  • 综述,围绕ER依赖转录与PI3K-AKT-mTOR、cyclin D-CDK4/6-RB-E2F及cyclin E-CDK2互联网络解读近期治疗进展。

主要发现

  • ER药理学已多样化出口服SERD、PROTAC降解剂、完全拮抗剂CERAN、共价拮抗剂SERCA、调节剂SERM及KAT6抑制等机制不同类别。
  • 最一致的治疗信号集中于ESR1突变场景。
  • 慢性多节点阻断的主要限制为耐受性天花板,突变选择性PI3Kα抑制剂及CDK4/CDK2选择性药物以选择性提升突破该限制。
  • 患者选择正从临床病理类别转向基于组织和/或ctDNA的基因组定义亚组,ctDNA还可用于动态监测和特定场景下的抢先切换。

临床怎么用

  • 以耐药分类为路线图,对腔内信号轴实施生物标志物引导的垂直阻断。
  • 利用组织和/或ctDNA进行基因组亚组选择,并在特定场景用ctDNA动态监测和抢先切换。
  • 优先关注ESR1突变场景及突变选择性PI3Kα、CDK4/CDK2选择性药物的耐受性优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer is driven by an interconnected signaling network centered on estrogen receptor (ER)-dependent transcription. ER signaling interacts bidirectionally with the PI3K-AKT-mTOR pathway and converges with it on the cyclin D-CDK4/6-RB-E2F machinery governing G1-S progression, a circuitry that cyclin E-CDK2 can reinforce or bypass during resistance. This network is now actionable at multiple levels, and recent years have produced an exceptional density of practice-changing innovations. Rather than cataloging individual agents, we interpret these advances as successive efforts to target one interdependent system, organized around three insights. First, ER pharmacology has diversified into mechanistically distinct classes -oral SERDs, PROTAC degraders, complete antagonists (CERANs), covalent antagonists (SERCAs) and modulators (SERMs), joined by KAT6 inhibition- yet the most consistent signal concentrates in the ESR1-mutant setting, a lesson in biomarker-gated development. Second, the principal constraint has been the tolerability ceiling of chronic multi-node blockade; mutant-selective PI3Kα inhibitors and CDK4- and CDK2-selective agents are defined less by new targets than by the selectivity that lifts that ceiling. Third, patient selection is shifting from clinicopathological categories to genomically defined subgroups assessed on tissue and/or circulating tumor DNA (ctDNA), with ctDNA additionally enabling dynamic monitoring and pre-emptive switching in selected scenarios. Synthesizing this landscape, we propose that the contemporary resistance taxonomy can serve as a therapeutic decision roadmap for durable, tolerable, biomarker-guided vertical blockade of the luminal axis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Caltavituro A, Giordano A, De Angelis C, et al. Drugging the luminal axis end to end: A review of next-generation endocrine and targeted therapies in HR + /HER2- metastatic breast cancer. Eur J Cancer. 2026. PMID: 42962412. doi:10.1016/j.ejca.2026.117794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。